Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Efficacy and safety of trelagliptin in combination with insulin therapy in Japanese patients with type 2 diabetes: Results from a randomized, Phase IV study.

Kaku K, Kuroda S, Ishida K, Umeda Y.

Diabetes Obes Metab. 2018 Oct;20(10):2490-2493. doi: 10.1111/dom.13397. Epub 2018 Jul 2.

2.

Binding behavior of trelagliptin and human serum albumin: Molecular docking, dynamical simulation, and multi-spectroscopy.

Gan R, Zhao L, Sun Q, Tang P, Zhang S, Yang H, He J, Li H.

Spectrochim Acta A Mol Biomol Spectrosc. 2018 Sep 5;202:187-195. doi: 10.1016/j.saa.2018.05.049. Epub 2018 May 19.

PMID:
29787915
3.

Different Spectrophotometric Methods for Simultaneous Determination of Trelagliptin and Its Acid Degradation Product.

Mowaka S, Ayoub BM, Hassan MA, Zaghary WA.

J Anal Methods Chem. 2018 Jan 30;2018:7370651. doi: 10.1155/2018/7370651. eCollection 2018.

4.

Suitability of various chromatographic and spectroscopic techniques for analysis and kinetic degradation study of trelagliptin.

Zaghary WA, Mowaka S, Hassan MA, Ayoub BM.

Sci Rep. 2017 Dec 8;7(1):17255. doi: 10.1038/s41598-017-17642-1.

5.

Satisfaction and efficacy of switching from daily dipeptidyl peptidase-4 inhibitors to weekly trelagliptin in patients with type 2 diabetes-Randomized controlled study.

Oita M, Miyoshi H, Ono K, Nakamura A, Cho KY, Nomoto H, Yamamoto K, Omori K, Manda N, Kurihara Y, Aoki S, Atsumi T.

Endocr J. 2018 Feb 26;65(2):141-150. doi: 10.1507/endocrj.EJ17-0303. Epub 2017 Oct 31.

6.

Effect of Trelagliptin on Quality of Life in Patients with Type 2 Diabetes Mellitus: Study Protocol.

Ishii H, Suzaki Y, Miyata Y.

Diabetes Ther. 2017 Dec;8(6):1415-1425. doi: 10.1007/s13300-017-0318-8. Epub 2017 Oct 26.

7.

Development of a validated HPLC method for the quantitative determination of trelagliptin succinate and its related substances in pharmaceutical dosage forms.

Luo Z, Chen X, Wang G, Du Z, Ma X, Wang H, Yu G, Liu A, Li M, Peng W, Liu Y.

Eur J Pharm Sci. 2018 Jan 1;111:458-464. doi: 10.1016/j.ejps.2017.10.028. Epub 2017 Oct 21.

PMID:
29066384
8.

Efficacy and Patient Satisfaction of the Weekly DPP-4 Inhibitors Trelagliptin and Omarigliptin in 80 Japanese Patients with Type 2 Diabetes.

Tosaki T, Kamiya H, Yamamoto Y, Himeno T, Kato Y, Kondo M, Yamada Y, Inagaki A, Tsubonaka K, Oshiro C, Katayama T, Hayasaki T, Nakaya Y, Fujiyoshi H, Nakamura J.

Intern Med. 2017 Oct 1;56(19):2563-2569. doi: 10.2169/internalmedicine.8184-16. Epub 2017 Sep 6.

9.
10.

Safety evaluation of trelagliptin in the treatment of Japanese type 2 diabetes mellitus patients.

Kaku K.

Expert Opin Drug Saf. 2017 Nov;16(11):1313-1322. doi: 10.1080/14740338.2017.1369526. Epub 2017 Aug 29. Review.

PMID:
28829213
11.

Effect of trelagliptin on vascular endothelial functions and serum adiponectin level in patients with type 2 diabetes: a preliminary single-arm prospective pilot study.

Ida S, Murata K, Betou K, Kobayashi C, Ishihara Y, Imataka K, Uchida A, Monguchi K, Kaneko R, Fujiwara R, Takahashi H.

Cardiovasc Diabetol. 2016 Nov 4;15(1):153.

12.

[Crystal structure and crystal form stability of trelagliptin succinate].

Ye JL, Zhou XB, Wu SX, Sun MY, Gu JM, Hu XR.

Yao Xue Xue Bao. 2016 Nov;51(11):1759-64. Chinese.

PMID:
29908134
13.

A rapid and sensitive UHPLC-MS/MS assay for the determination of trelagliptin in rat plasma and its application to a pharmacokinetic study.

Hu XX, Lan T, Chen Z, Yang CC, Tang PF, Yuan LJ, Hu GX, Cai JP.

J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Oct 15;1033-1034:166-171. doi: 10.1016/j.jchromb.2016.08.024. Epub 2016 Aug 16.

PMID:
27561183
14.

Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism.

Grimshaw CE, Jennings A, Kamran R, Ueno H, Nishigaki N, Kosaka T, Tani A, Sano H, Kinugawa Y, Koumura E, Shi L, Takeuchi K.

PLoS One. 2016 Jun 21;11(6):e0157509. doi: 10.1371/journal.pone.0157509. eCollection 2016.

15.

Identification, characterization and HPLC quantification of process-related impurities in Trelagliptin succinate bulk drug: Six identified as new compounds.

Zhang H, Sun L, Zou L, Hui W, Liu L, Zou Q, Ouyang P.

J Pharm Biomed Anal. 2016 Sep 5;128:18-27. doi: 10.1016/j.jpba.2016.04.041. Epub 2016 May 10.

PMID:
27209451
17.

First novel once-weekly DPP-4 inhibitor, trelagliptin, for the treatment of type 2 diabetes mellitus.

Kaku K.

Expert Opin Pharmacother. 2015;16(16):2539-47. doi: 10.1517/14656566.2015.1099630. Epub 2015 Nov 2. Review.

PMID:
26523434
18.

Trelagliptin: First Global Approval.

McKeage K.

Drugs. 2015 Jul;75(10):1161-4. doi: 10.1007/s40265-015-0431-9. Review.

PMID:
26115728
19.

Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study.

Inagaki N, Onouchi H, Maezawa H, Kuroda S, Kaku K.

Lancet Diabetes Endocrinol. 2015 Mar;3(3):191-7. doi: 10.1016/S2213-8587(14)70251-7. Epub 2015 Jan 19.

PMID:
25609193

Supplemental Content

Loading ...
Support Center